This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
このページの翻訳は実験的なもので、現在 開発中です。お待ちしております！
Global Blood Therapeutics 過去の業績
過去 基準チェック /06
主要情報
-20.1%
収益成長率
-12.1%
EPS成長率
| Biotechs 業界の成長 | -14.6% |
| 収益成長率 | 74.8% |
| 株主資本利益率 | -272.4% |
| ネット・マージン | -137.3% |
| 前回の決算情報 | 30 Jun 2022 |
最近の業績更新
Recent updates
収支内訳
収支内訳
Global Blood Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 22 | 235 | -322 | 303 | 227 |
| 31 Mar 22 | 211 | -310 | 283 | 214 |
| 31 Dec 21 | 195 | -303 | 267 | 212 |
| 30 Sep 21 | 180 | -277 | 248 | 194 |
| 30 Jun 21 | 165 | -266 | 234 | 184 |
| 31 Mar 21 | 149 | -249 | 222 | 166 |
| 31 Dec 20 | 124 | -248 | 211 | 155 |
| 30 Sep 20 | 85 | -282 | 196 | 179 |
| 30 Jun 20 | 48 | -286 | 171 | 178 |
| 31 Mar 20 | 16 | -291 | 147 | 180 |
| 31 Dec 19 | 2 | -267 | 117 | 175 |
| 30 Sep 19 | 0 | -220 | 88 | 146 |
| 30 Jun 19 | 0 | -199 | 71 | 140 |
| 31 Mar 19 | 0 | -182 | 57 | 136 |
| 31 Dec 18 | 0 | -174 | 51 | 131 |
| 30 Sep 18 | 0 | -166 | 46 | 127 |
| 30 Jun 18 | 0 | -152 | 43 | 114 |
| 31 Mar 18 | 0 | -135 | 38 | 100 |
| 31 Dec 17 | 0 | -117 | 31 | 88 |
| 30 Sep 17 | 0 | -103 | 27 | 76 |
| 30 Jun 17 | 0 | -95 | 24 | 72 |
| 31 Mar 17 | 0 | -89 | 22 | 66 |
| 31 Dec 16 | 0 | -82 | 20 | 61 |
| 30 Sep 16 | 0 | -71 | 20 | 52 |
| 30 Jun 16 | 0 | -65 | 16 | 49 |
| 31 Mar 16 | 0 | -58 | 13 | 43 |
質の高い収益: G5B is currently unprofitable.
利益率の向上: G5B is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: G5B is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.
成長の加速: Unable to compare G5B's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: G5B is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-16.7%).
株主資本利益率
高いROE: G5B has a negative Return on Equity (-272.44%), as it is currently unprofitable.